newsfilter
← Latest News
GlobeNewswire·

Sio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase 1/2 Trial of AXO-AAV-GM1 for GM1 Gangliosidosis

- Generally well-tolerated with a favorable safety profile in five patients- Serum beta-galactosidase enzyme activity increased in all patients at all timepoints between Day 7 and Month 6,...